Leerink Partners analyst Seamus Fernandez weighed in on Merck (NYSE: MRK) after Keytruda steals the show at ESMO.Fernandezcommented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE